Ultra-high speed AO-OCT clinical system to image ganglion cells and microglia

超高速 AO-OCT 临床系统对神经节细胞和小胶质细胞进行成像

• 批准号: 10705315
• 负责人: Mircea Mujat
• 金额: $ 84.18万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10705315
• 关键词: Area; Biological Markers; Blindness; Buffers; Cells; Clinical; Collaborations; Communities; Data; Degenerative Disorder; Detection; Development; Diabetes Mellitus; Diabetic Retinopathy; Diagnosis; Disease; Disease Marker; Disease Progression; Ear; Elements; Evaluation; Eye; Ganglia; Glaucoma; Goals; Government; Human; Image; Imaging Techniques; Investigation; Label; Lateral; Legal patent; Macrophage; Market Research; Massachusetts; Microglia; Monitor; Morphologic artifacts; Motion; Nerve Fibers; Neurosciences; Noise; Ophthalmology; Ophthalmoscopes; Optics; Pathogenesis; Patients; Performance; Persons; Phagocytosis; Phase; Play; Recording of previous events; Research; Resolution; Retina; Retinal Degeneration; Retinal Diseases; Retinal Ganglion Cells; Role; Scanning; Severity of illness; Signal Transduction; Source; Spatial Distribution; Speed; Structure; System; Technology; Testing; Time; Vision; Visualization; adaptive optics; adaptive optics scanning laser ophthalmoscopy; axon injury; clinical diagnostics; clinical imaging; commercialization; cost; density; design; diagnostic platform; experience; ganglion cell; healthy volunteer; human subject; imager; imaging approach; imaging platform; imaging system; improved; innovation; instrument; interest; lens; meter; next generation; novel; novel therapeutics; optical imaging; optical polarization; physical science; programs; prototype; retinal imaging; routine imaging; specific biomarkers; tool

Project Summary/Abstract There is currently a significant need for new imaging techniques that may enable accurate quantification of biomarkers for detection, diagnosis, and monitoring of retinal diseases progression. Physical Sciences Inc. (PSI), Massachusetts Eye and Ear (MEE), and Joslin Diabetes Center (JDC) propose to develop a clinical tool able to routinely image retinal ganglion cells (RGCs) and to characterize microglia spatial distribution and temporal dynamics in live human eyes using a label-free adaptive optics (AO) imaging approach for improved diagnosis and treatment of glaucoma and diabetic retinopathy (DR). An ultra-high speed AO-OCT system will be designed and built based on a number of recently demonstrated innovations: lens-based design, ultra-high speed to eliminate motion artifacts, buffered swept source (SS) and dual beam approach to increase A-line rate to the MHz range, adaptive lens, dual-axis MEMS for raster scanning, and the use of polarization optics to eliminate specular reflections on optical elements. The retinal imager will be tested in a clinical setting at MEE and JDC on a large group of glaucoma and DR subjects experiencing a wide range of disease severity. Specific biomarkers for glaucoma and DR will be defined based on patient data acquired by our collaborators from MEE and JDC. PSI has a long, successful history of developing and commercializing high-resolution retinal imagers for the ophthalmic research market which gives us a competitive advantage in developing and maturing this platform that enables routine clinical imaging of human subjects and motivates a Direct to Phase II approach. A successful program and subsequent Phase III commercial development will provide clinicians with high performance retinal imaging for glaucoma and DR investigations at a lower cost and improved functionality superior to other non-AO retinal imagers. Early adaptors of this technology within the research community will grow our understanding of vision and its disruption by glaucoma and DR and will investigate the effects of new drugs and therapies. The ability to visualize ganglion and macrophage cells without fluorescent labeling in the human eye represents an important advance for both ophthalmology and neuroscience, which will lead to identification of novel disease biomarkers and new avenues of exploration in disease progression.

项目概要/摘要 目前迫切需要新的成像技术来实现准确的成像 用于检测、诊断和监测视网膜疾病进展的生物标志物的量化。 物理科学公司 (PSI)、马萨诸塞州眼耳科 (MEE) 和乔斯林糖尿病中心 (JDC) 建议开发一种能够对视网膜神经节细胞（RGC）进行常规成像并表征的临床工具 使用无标记自适应光学器件研究活体人眼中小胶质细胞的空间分布和时间动态 (AO) 成像方法可改善青光眼和糖尿病视网膜病变 (DR) 的诊断和治疗。 超高速AO-OCT系统将基于近期的多项研究成果进行设计和构建。 展示的创新：基于镜头的设计、消除运动伪影的超高速、缓冲扫描 光源 (SS) 和双光束方法可将 A 线速率提高到 MHz 范围、自适应镜头、双轴 用于光栅扫描的 MEMS，以及使用偏振光学器件来消除光学器件上的镜面反射 元素。视网膜成像仪将在 MEE 和 JDC 的大量临床环境中进行测试 青光眼和 DR 受试者的疾病严重程度各不相同。青光眼的特异性生物标志物 DR 将根据我们的合作者从 MEE 和 JDC 获取的患者数据进行定义。 PSI 在高分辨率视网膜成像仪的开发和商业化方面拥有悠久而成功的历史 眼科研究市场为我们在开发和成熟这一领域提供了竞争优势 能够对人类受试者进行常规临床成像并推动直接进入 II 期临床的平台 方法。一个成功的项目和随后的第三阶段商业开发将为临床医生提供 具有用于青光眼和 DR 研究的高性能视网膜成像，成本更低且改进 功能优于其他非 AO 视网膜成像仪。该技术在研究中的早期应用 社区将增进我们对青光眼和 DR 对视力及其破坏的了解，并将进行调查 新药物和疗法的效果。无需观察即可观察神经节细胞和巨噬细胞的能力 人眼中的荧光标记代表了眼科和眼科学的重要进步 神经科学，这将导致新疾病生物标志物的识别和新的探索途径 在疾病进展中。